Alumis heads toward Q3 2026 LUMUS readout for oral TYK2 drug in lupus
The 408-patient Phase 2b trial will report whether ESK-001 beats placebo on BICLA response at Week 48, the first test of Alumis's oral TYK2 inhibitor outside psoriasis.
Executive Summary
- Alumis is approaching a placebo-controlled efficacy readout that will show for the first time whether its oral TYK2 inhibitor works in systemic lupus, a disease where the company's psoriasis data cannot yet answer the question.
- The sponsor has held the same reporting window across every disclosure for a year, and the trial's operational profile shows no enrollment cut and no completion-date slip since the timeline was last set, which argues the delay risk here is limited.
- No other clinical-stage program combines TYK2 inhibition with a lupus indication, leaving this readout without a direct precedent to benchmark against inside its own mechanism-indication pairing.
- A positive result would extend validation of Alumis's TYK2 platform beyond psoriasis into a second autoimmune disease, while a miss would leave the company's broader immunology thesis resting on a narrower, single-indication base.
The trial and its bar
LUMUS (NCT05966480) is a randomized, double-blind, placebo-controlled Phase 2b study testing multiple doses of ESK-001 against placebo in adults with moderately-to-severely active, autoantibody-positive SLE. The primary endpoint compares the proportion of patients achieving a BILAG-based Composite Lupus Assessment (BICLA) response, a validated measure of overall disease-activity improvement, at Week 48 between ESK-001 doses and placebo. The trial enrolled 408 patients across sites in the United States, India, Mexico, Poland, and eight other countries, and closed enrollment as of the company's July 2025 announcement. Fourteen secondary endpoints, including fatigue, corticosteroid use, flare rate, and quality-of-life measures, will provide texture around any primary result. NCT05966480+1Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusNCT05966480Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a ...Jul 24, 2025
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Why lupus, not psoriasis
Alumis's chief medical officer, Jorn Drappa, said ESK-001 "achieved full, sustained target inhibition and was generally well tolerated" in the company's psoriasis program, and that the drug "downregulates key cytokines and disease biomarkers relative to SLE". That psoriasis data establishes pharmacologic activity on the TYK2 pathway but does not itself establish efficacy in lupus, where interferon-driven inflammation plays a distinct role. LUMUS is the trial that will test whether target engagement translates into a clinical response specific to SLE. AlumisAlumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a ...Jul 24, 2025
Operational read
The trial's primary completion date moved once, from May 2025 to July 1, 2026, in a November 2024 registry update, and has not changed since. Enrollment grew from 388 to 408 patients when the trial's status shifted to Active, not recruiting in August 2025, a change inside the range the operational model treats as routine rather than a cut or a shortfall. The sponsor has repeated the same Q3 2026 window, July 1 through September 30, across six disclosures dated from July 2025 through May 2026, with no evidence of guidance slippage. NCT05966480+1Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusNCT05966480Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a ...Jul 24, 2025
The competitive field
Among trials that share ESK-001's TYK2 target, the closest analog is Bristol-Myers Squibb's deucravacitinib, which is running two Phase 3 trials in SLE with a primary completion expected in October 2026, roughly the same window as LUMUS. No trial in the broader SLE landscape pairs TYK2 inhibition with lupus at Phase 2 besides LUMUS itself, leaving the mechanism-indication combination without a resolved precedent inside SLE specifically. The nearest indication-level comparators, including AstraZeneca's anifrolumab (an IFNAR1 antagonist), UCB's dapirolizumab pegol (a CD40L-targeting biologic), and Janssen's nipocalimab (an FcRn antagonist), work through different mechanisms and do not bear directly on whether TYK2 inhibition itself moves BICLA response.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.